期刊文献+

降压治疗对原发性高血压患者血浆Fib、t-PA及PAI-1浓度变化的影响 被引量:1

The Effects of Antihypertensives in the Changes of the Concentration of Plasma fibriongen,tissue-type plasminogen activator and Plasminogen activator inhibitor-1 in Patients with Elementary Hypertension
下载PDF
导出
摘要 目的:研究原发性高血压(EH)患者血液纤维系统改变及降压药物治疗对其影响,探讨EH患者血栓前状态(PTS)发生机制及降压治疗减少血栓事件的机理。方法:用酶联免疫吸附(ELISA)竞争及双抗体夹心法对30例EH患者分别于降压治疗前后测定外周静脉血浆纤维蛋白原(Fib)、组织型纤溶酶原激活物(t-PA)及组织型纤溶酶原激活物抑制物-1(PAI-1)浓度变化,并与30例健康体检者相比较。结果:EH患者降压治疗前血浆Fib,t-PA及PAI-1浓度比正常对照组明显升高;福辛普利与贝尼地平联合降压治疗6周后与治疗前相比明显降低。结论:EH患者体内存在PTS与纤维系统低下有关,福辛普利与贝尼地平联合降压治疗能改善PTS。 Objective:To study the changes of fibrinolysis patients with essential hypertension (EH) and the effects of antihypertensives in it ,and explore the mechanism of prothrombotie state (PTS) in EH and the possible reason of antihypertensive treatment on decreasing the accident of thrombosis. Methods :ELISA was used to measure plasma fibriongen (Fib),tissue-type plasminogen activator(t-PA) and Plasminogen activator inhibitor-1 (PAI-1) in 30 patients with EH before and after antihypertensive treatment for 6 weeks, Serum levels of Fib,tPA and PAI-1 were compared with those in 30 healthy subjects. Results:The concentration of plasma Fib,t-PA and PAI-1 in EH group were significantly higher than that in control group which also significantly lowered after 6 weeks treatment with ACEI and CCB. Conclusion:PTS in EH is relevant to hypofibrinolysis and the combining treatment of ACEI and CCB can release PTS in patients with EH.
出处 《中国误诊学杂志》 CAS 2008年第28期6811-6813,共3页 Chinese Journal of Misdiagnostics
关键词 高血压/药物疗法 纤维蛋白原/分析 组织型纤溶酶原激活物/血液 纤溶酶原激活物抑制物1/血液 福辛普利/治疗应用 抗高血压药/治疗应用 Hypertension/drug therapy Fibrinogen/analysis Tissue Plasminogen Activator/blood PlasminogenActivator Inhibitor 1/blood Fosinopril/therapeutic use Antihypertensive Agents/therapeutic use
  • 相关文献

参考文献9

  • 1Sechi LA, Aingaro L, Catena C, et al. Relationship of fibrinogen levels and hemostatie abnormalities with organ damage in hypertension[J]. Hypertension, 2000,36 (6) : 978-985. 被引量:1
  • 2Lip GY,Blann AD,Zarifis J,et al. Soluble adhesion molecule Pseleetin and endothelial dysfunction in essential hypertension: implications for atherogensis? Apreliminary report[J]. J Hypertens,1995,13(12pt):1674-1678. 被引量:1
  • 3韩崇旭,李锦堂,苏天水,王兆钺,阮长耿.心脑血管疾病止血与纤溶相关指标的临床研究[J].中华血液学杂志,2001,22(3):147-149. 被引量:19
  • 4许俊堂,王荣山.血栓相关的血液学指标及其意义[J].中华检验医学杂志,2000,23(6):382-384. 被引量:37
  • 5张润峰,李霞.高血压病与血栓前状态[J].高血压杂志,2004,12(1):8-11. 被引量:15
  • 6Nadar S,Lip GY, The prothrombotic state in hypertension and the effects of antihypertensive treatment [J]. Curr Pharm Des, 2003,9(21):1715-1732. 被引量:1
  • 7Nadar S, Blann AD, Lip GY. Antihypertensive therapy and endothelial function [J]. Curr Pbarm Des, 2004, 10 (29): 3607-3614. 被引量:1
  • 8Perticone F,Ceravolo R,Maio R ,et al. Calcium antagonst isradipine improves abnormal endothelium dependent vasodilation in never treated hypertensive patients[J]. Cardio Vase Res,1999, 41:299-306. 被引量:1
  • 9Ranieri G, Filitti V, Andriani A, et al. Effects of isradipine sustained release on platelet function and fibrinolysis in essential hy pertensive with or without other risk factors[J]. Cariovasc Drugs Ther,1996,10:119-123. 被引量:1

二级参考文献37

共引文献66

同被引文献7

引证文献1

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部